Methylcellulose
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Using the drug-repurposing evaluation report template to produce the UK pharmacist-facing report for Methylcellulose (DB11228).
Methylcellulose: From Pharmaceutical Excipient to Osteoarthritis (Predicted)
One-Sentence Summary
Methylcellulose is a cellulose derivative used pharmaceutically as an excipient, hydrogel/scaffold carrier and bulk-forming agent; no approved therapeutic indication is recorded in this evidence pack. The TxGNN model predicts it may be effective for Osteoarthritis, with 0 clinical trials and 18 publications currently associated — though nearly all of these describe methylcellulose acting only as an inert delivery vehicle rather than as an active treatment.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no approved indication on record. Methylcellulose is primarily used as a pharmaceutical excipient / bulk-forming carrier |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 95.21% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for methylcellulose (data gap). Based on the literature captured in this evidence pack, methylcellulose is a cellulose-derived polymer used almost exclusively as a pharmaceutical excipient — a thickening agent, bulk-forming laxative, ophthalmic lubricant, and, most relevantly here, a thermosensitive hydrogel/scaffold carrier. It is not described anywhere in the supporting literature as a pharmacologically active anti-inflammatory or chondroprotective agent in its own right.
Nearly all 18 associated publications feature methylcellulose (or the closely related carboxymethylcellulose) as an inert delivery vehicle for genuinely active agents — nanozymes, TIMP-3 protein, mesenchymal stromal cell spheroids, celecoxib, and meloxicam — used to treat osteoarthritis. This suggests the TxGNN knowledge-graph association may be capturing a “drug-delivery-carrier ↔ disease” relationship rather than a true drug-treats-disease relationship, which substantially weakens the pharmacological plausibility of this prediction.
Consequently, the reasoning linking methylcellulose to a direct therapeutic effect in osteoarthritis is speculative and should not be interpreted as evidence of intrinsic disease-modifying activity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40354857 | 2025 | Preclinical/Formulation | Int J Biol Macromol | Pluronic F127/methylcellulose hydrogel used as a percutaneous carrier for nanozymes in an OA model; methylcellulose is a formulation excipient, not the active agent |
| 41054792 | 2025 | Preclinical/Formulation | Artif Cells Nanomed Biotechnol | Methylcellulose–carboxymethyl chitosan thermosensitive hydrogel used to deliver mesenchymal stromal cell spheroids for cartilage regeneration |
| 39486930 | 2025 | Preclinical/Formulation | Carbohydr Polym | Methyl cellulose-based interpenetrating network hydrogel; injectable, stimuli-responsive drug-release platform |
| 32027902 | 2020 | Preclinical/Formulation | Int J Biol Macromol | Carboxymethyl chitosan–methylcellulose–pluronic hydrogel used to encapsulate meloxicam-loaded nanoparticles |
| 37321710 | 2023 | Preclinical/Formulation | Carbohydr Polym | Sulfated carboxymethylcellulose used to stabilise and deliver TIMP-3 protein in OA models |
| 35588980 | 2022 | Preclinical/Formulation | Int J Biol Macromol | Sulfated carboxymethylcellulose scaffold for TIMP-3 delivery, proposed as disease-modifying strategy for OA |
| 25468298 | 2015 | Preclinical | J Biomech | Carboxymethylcellulose among several polymers tested for crosslinked resurfacing of damaged articular cartilage |
| 26752990 | 2015 | Preclinical/Formulation | Res Pharm Sci | Sodium carboxymethylcellulose/HPMC gel used as a transdermal iontophoretic carrier for celecoxib |
| 33499342 | 2021 | Preclinical | Molecules | Carboxymethylcellulose entrapped in a PVA network as a scaffold for cartilage tissue engineering |
| 36079990 | 2022 | Preclinical/Formulation | Nanomaterials | Proanthocyanidin transferosomes loaded into a 4% methylcellulose gel as a transdermal delivery system for OA |
UK Market Information
No UK marketing authorisations are currently on record for this product; market status is Not marketed (0 authorisations found in the source dataset). Please verify directly with the MHRA product database and BNF, as methylcellulose is widely available in the UK as an excipient/component of licensed bulk-forming laxative and ophthalmic lubricant products under other brand entries not captured in this evidence pack.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Key warnings, contraindications and drug-interaction data are currently marked as data gaps in this evidence pack (see DG001, Blocking severity) — this must be resolved before any S1 safety assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence base is limited to preclinical formulation studies (Evidence Level L4) in which methylcellulose functions as an inert delivery vehicle rather than an active therapeutic agent, with no clinical trials and no mechanism-of-action data available. The prediction likely reflects a delivery-carrier association in the knowledge graph rather than a genuine pharmacological signal.
To proceed, the following is needed:
- MHRA/SmPC-sourced mechanism of action data (currently data gap DG002)
- MHRA/SmPC warnings, contraindications and interaction data (currently data gap DG001, Blocking)
- Confirmation of original approved indication(s) for methylcellulose in the UK
- Direct pharmacological or clinical evidence of methylcellulose as an active (not carrier) agent in osteoarthritis before any further development consideration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.